A PHASE I, MULTICENTER, OPEN-LABEL SAFETY, PHARMACOKINETIC AND PRELIMINARY EFFICACY STUDY OF WILD-TYPE SPARING EGFR INHIBITOR, AC0010MA, IN ADULT PATIENTS WITH PREVIOUSLY TREATED EGFRMUT AND ACQUIRED T790M MUTATION NON-SMALL CELL LUNG CANCER (NSCLC)
2017-002743-16CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑASFundación Jiménez DíazInvestigador: MORENO GARCIA VICTOR
